Navigation Links
Genzyme Announces Results of Clinical Trial of Hylastan

CAMBRIDGE, Mass., July 05, 2007 /PRNewswire-FirstCall/ -- Genzyme Corp. today announced top-line results from a pivotal study investigating the safety and efficacy of hylastan in treating pain in patients with osteoarthritis (OA) of the knee. Hylastan is being developed within Genzyme's program to introduce a viscosupplementation product that can be delivered through a single knee injection. The goal of this effort is to simplify OA pain management, reduce the overall cost of therapy and advance a treatment option that may expand the benefits of viscosupplementation to a broader number of patients.

Genzyme's development program also includes Synvisc-One(TM), an investigational combined-dose regimen of Synvisc(R) (hylan G-F 20) provided in a single injection, which the company is currently seeking to market in the United States and Europe. Genzyme has submitted an application to the FDA for Synvisc-One, and later this month will apply for a CE Mark to introduce Synvisc-One in Europe. Regulatory action on both applications is expected this year. Results from the successful pivotal study of Synvisc-One were presented last month at the Annual European Congress of Rheumatology.

The pivotal trial of hylastan was a double-blind, active-control study involving nearly 400 patients with osteoarthritis of the knee enrolled at 27 sites in North America and Europe. Patients were randomized to receive two intra-articular injections of hylastan delivered two weeks apart, a single injection of hylastan, or an injection of a corticosteroid. Patients were evaluated for 26 weeks following treatment. Results showed a statistically significant and clinically meaningful reduction in knee pain compared to baseline for each of the three treatment arms. However, the difference in pain reduction between patients treated with hylastan and patients treated with a steroid was not significant, and the trial did not meet its pr
'"/>




Page: 1 2 3 4

Related medicine technology :

1. Genzyme Announces Data from First Phase 3 Study of Tolevamer in Patients with C. difficile Associated Diarrhea
2. Genzyme Announces Results of Clinical Trials Investigating Powder Form of Sevelamer Carbonate
3. Genzyme Announces Results of Clinical Trials Investigating Powder Form of Sevelamer Carbonate
4. Genzyme and Bayer HealthCare Announce Detailed Interim Two-Year Alemtuzumab in Multiple Sclerosis Data Presented at AAN
5. Genzyme Announces Successful Completion of Study Investigating Sevelamer Carbonate in Patients With Chronic Kidney Disease
6. Antisoma Announces Further Data From ASA404 Ovarian Cancer Trial
7. Neose Announces Presentation of Positive Preclinical Data on GlycoPEGylated Factor VIIa at the XXI Congress of the International Society on Thrombosis and Haemostasis
8. Biofrontera AG Announces Clinical Study Confirms Excellent Efficacy of BF-200 ALA In Actinic Keratosis
9. YM BioSciences Announces Secondary Efficacy and Safety Findings in Randomized Phase IIB Aerolef Trial
10. BioSante Pharmaceuticals Announces New Findings for Potential Bird Flu Vaccine
11. Portola Pharmaceuticals Announces Positive Data from a Phase II Study of its Factor Xa Inhibitor at the XXI Congress of the International Society on Thrombosis and Haemostasis
Post Your Comments:
*Name:
*Comment:
*Email:
TAG: Genzyme Announces Results Clinical Trial Hylastan
(Date:10/2/2014)... , Oct. 2, 2014   West Pharmaceutical ... global leader in innovative solutions for injectable drug administration, ... operations to include a new site in ... packaging components for insulin injector cartridges and other high-value ... pharmaceutical and biotech customers. Once operational, this new site ...
(Date:10/1/2014)... , Oct. 1, 2014   Plexus ... provider of Anesthesia Information Management Systems (AIMS), announced ... LLC , a wholly owned subsidiary of Quality ... information systems and connectivity solutions.  ... http://photos.prnewswire.com/prnh/20140930/149407 This partnership extends ...
(Date:10/1/2014)... NeuroCall, Inc., ("NeuroCall") announced today that it recently received ... Dr. Ricardo Garcia-Rivera , Founder and Chief Medical ... our quality of service has been recognized by The ... and continuity of care to patients of our expanding ... States ." NeuroCall currently provides ...
Breaking Medicine Technology:West Announces Plans for a New Pharmaceutical Component Manufacturing Plant in Ireland 2West Announces Plans for a New Pharmaceutical Component Manufacturing Plant in Ireland 3West Announces Plans for a New Pharmaceutical Component Manufacturing Plant in Ireland 4West Announces Plans for a New Pharmaceutical Component Manufacturing Plant in Ireland 5Plexus IS' Anesthesia Documentation Solution Strengthens NextGen Healthcare Product Offering 2Plexus IS' Anesthesia Documentation Solution Strengthens NextGen Healthcare Product Offering 3NeuroCall Awarded Joint Commission Accreditation 2
... , MINNEAPOLIS , Feb. 4 ... of state-of-the-art cardiac surgery products and services, today announced that it will ... , after the market close on Monday, March 1, 2010 . ... March 1, 2010 at 5:00 p.m. Eastern Time ( ...
... PITTSBURGH , Feb. 4 Mylan Inc. (Nasdaq: ... in connection with the filing of an Abbreviated New Drug Application ... Besylate and Atorvastatin Calcium Tablets 2.5/10 mg, 2.5/20 mg, 2.5/40 mg, ... mg, 10/40 and 10/80 mg. This product is the generic version ...
Cached Medicine Technology:ATS Medical Announces Fourth Quarter 2009 Earnings Release Date and Conference Call 2ATS Medical Announces Fourth Quarter 2009 Earnings Release Date and Conference Call 3Mylan Confirms First-to-File Patent Challenge Relating to Caduet(R) 2
(Date:10/2/2014)... October 02, 2014 Robins & ... the Associated Builders and Contractors (ABC) of Alabama. ... tonight’s banquet held at Sheraton Birmingham Hotel., ... Healthcare $10 Million to $25 Million, Obelisk Award ... Clinic, Federal Government $10 Million to $25 Million, ...
(Date:10/2/2014)... Maureen Salamon ... News) -- Middle-aged women with a neurotic personality style ... developing Alzheimer,s disease, new research suggests. Tracking 800 ... those who were most anxious, jealous and moody -- ... stress had double the risk of developing Alzheimer,s compared ...
(Date:10/2/2014)... HealthDay Reporter WEDNESDAY, Oct. 1, 2014 ... isn,t reduced by breast-feeding. Nor will delaying the introduction of ... diet help prevent celiac disease. Those are the ... 2 New England Journal of Medicine . The ... avoid celiac disease if mothers breast-feed their babies and introduce ...
(Date:10/1/2014)... of Adelaide have developed a model that could help ... from treatment - from their very first psychotic episode. ... factors, including clinical symptoms, cognitive abilities, MRI scans of ... , Speaking in the lead up to World Mental ... Psychiatry , Professor Bernhard Baune , says the ...
(Date:10/1/2014)... co-funded by the Engineering and Physical Sciences Research ... the UK,s vital industrial control systems which run, ... grid, and the rail network. , The ... hackers or malware infiltrating the systems behind our ... in Trustworthy Industrial Control Systems (RITICS), based at ...
Breaking Medicine News(10 mins):Health News:Robins & Morton wins nine awards from Associated Builders and Contractors 2Health News:Jealous, Moody Women May Face Higher Alzheimer's Risk, Study Says 2Health News:Jealous, Moody Women May Face Higher Alzheimer's Risk, Study Says 3Health News:Infant's Early Diet Doesn't Change Celiac Disease Risk, Study Finds 2Health News:Infant's Early Diet Doesn't Change Celiac Disease Risk, Study Finds 3Health News:Predicting the future course of psychotic illness 2Health News:£2.5 million to recognize and reduce cyber-attack threats to critical infrastructure 2
... new study in the Annals,of Internal Medicine adds ... patients for the bacterium MRSA (methicillin-resistant,Staphylococcus aureus) is ... The study, published yesterday, resulted in a 70%,reduction ... in the,Evanston Northwestern Healthcare System, located near Chicago., ...
... 2008, WASHINGTON, March 18 Following is the,National ... The Bulletin, which is free of charge and available ... the latest issues and news,affecting people with disabilities. To ... click on Online mailing list archives,select NCD-NEWS-L, click on ...
... One of the nations oldest and most respected non-profit ... fellowships to underrepresented minority students and scientists to attend ... 5-9. The American Physiological Society (APS), which administers the ... travel awards. , APS administers the program with financial ...
... and SHANGHAI, China, March 18 ,Flagship Global Health, ... Limited (CHC), listed on the Stock Exchange of ... a strategic alliance to,jointly utilize their resources and ... leading insurance companies, including,China Ping An and China ...
... safety tests and is relatively painless , , TUESDAY, March 18 ... veins proved safe in patients, according to the results of ... found that use of injectable Varisolve microfoam didn,t cause any ... patients with a common heart defect. , Since 1997, ...
... HILL, N.C., March 18 The Internet has ... leaders,haven,t lost sight of the value of an ... a relationship and high performing sales,groups -- irrespective ... of their time identifying and addressing existing clients, ...
Cached Medicine News:Health News:Evanston-Northwestern Study Proves Effectiveness of MRSA Screening to Reduce Hospital Infections 2Health News:National Council on Disability Monthly Bulletin for February, 2008 2Health News:National Council on Disability Monthly Bulletin for February, 2008 3Health News:National Council on Disability Monthly Bulletin for February, 2008 4Health News:52 minority scientists receive travel fellowships to Experimental Biology 2008 2Health News:52 minority scientists receive travel fellowships to Experimental Biology 2008 3Health News:Flagship Global Health and China HealthCare Holdings Form Strategic Alliance 2Health News:Flagship Global Health and China HealthCare Holdings Form Strategic Alliance 3Health News:New Foam Treatment for Varicose Veins 2Health News:High Performing Sales Forces Follow Same Path to Excellence 2
AST (SGOT) R1 + R2. Automated analyzer test kits....
Intended for the quantitative determination of aspartate aminotransferase activity in serum or plasma. Reaction: Kinetic. Wavelength: 340 nm. Linearity: 268 U/L at 30C. Two vials, dry powder reagents...
The Midas II Stainer is an automated slide stainer designed for use in hematology and microbiology laboratories....
... TST 40 tissue stainer is an "assembly-line ... in histology and cytology laboratories. Programmable continuous ... stains big quantities of slides in short ... in combination with a continuous working principle ...
Medicine Products: